RxDoctor Payments Data

Chris Calaway

Optometrist · Barberton, OHNPI 1639165640

Payments from drug & device makers

$1,462in general payments, 2019–2025

Across 58 payments — averaging $25.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Coopervision Inc.$354
  • Johnson & Johnson Vision Care, Inc.$151
  • AbbVie$127
  • Aerie Pharmaceuticals, Inc.$122
  • Oyster Point Pharma, Inc.$118
  • Novartis$84
  • plus $504 from 14 others

What the payments were for

  • Food & beverage$1,44899%
  • Entertainment$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,462 in reported general payments places this provider in the 65th percentile of 1,995 optometrist providers in Ohio.

See all optometrist providers in Ohio

Medicare billing

Part B allowed, 2024
$76,364
Medicare patients
446
Services billed
770

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine77$75,003
LumiganBimatoprost44$20,196
XiidraLifitegrast18$17,553
Cyclosporine20$11,196
TyrvayaVarenicline Tartrate11$6,276
VyzultaLatanoprostene Bunod12$4,213
Latanoprost312$4,176
Timolol Maleate41$1,773
Brimonidine Tartrate21$1,664
Travoprost17$967
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat35$574
Tobramycin-DexamethasoneTobramycin/Dexamethasone15$563
Epinastine Hcl12$491
Prednisolone Acetate16$444
Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim27$187

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$127$95,199121 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$41$21,76730 claims
Oyster Point Pharma, Inc.Tyrvaya$118$6,27611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,995 optometrist providers in Ohio.

Other optometrist in Barberton

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →